A Study of RG1662 in Individuals With Down Syndrome

Summary

This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is 38 days.

Timeline

Start

2011-11

Primary completion

2013-09

Completion

2013-09

Drugs

Indications